Smart Imaging for Metabolic Associated Fatty Liver Disease
Date: June 30, 2020
Time: 3 PM PST | 5 PM CST | 11 PM BST
Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of abnormally high fat in the liver, after the exclusion of secondary etiologies such as significant alcohol consumption, among others. Because of this rather loose definition, many experts have recently suggested that Metabolic (dysfunction) Associated Fatty Liver Disease “MAFLD” is a more appropriate term.
With increasing obesity and diabetes, MAFLD is becoming a growing problem worldwide, affecting an estimated 70 million American adults.
As a silent disease it is often detected because of abnormal results for unrelated issues or annual screenings. Currently, treatments for MAFLD include mostly lifestyle modification interventions, such as weight loss and exercise. Drugs are expected to come to market this year.
In this webinar we will discuss how smart imaging techniques, such as LiverMultiScan® are improving the clinical pathway for patients with MAFLD, and how to integrate this into your practice.
- Understanding the links between obesity, diabetes and fatty liver disease.
- How LiverMultiScan empowers physicians to best care for patients with MAFLD.
- How patients with MAFLD are at higher risk of severe illness from COVID-19
- How this smart imaging technology compares to other non-invasive liver tests as an aid to diagnose, monitor and predict liver disease outcomes
- Integrating smart imaging into your practice.
Carlos Duncker, MD, PhD
Medical Science Liaison at Perspectum
Carlos started his career as an MD and completed residency programs in Internal Medicine and Nuclear Medicine as well as a PhD in Medicine and Surgery. Carlos was previously the head of the Nuclear Medicine and Molecular Imaging Department at the Children’s Hospital of Mexico, was Medical Advisor to the National Commission of Nuclear Safety and Safeguards and was Professor of Medical Physics at Autonomous National University of Mexico for several years. He has published 176 medical papers and was a Reviewer for the European Journal of Nuclear Medicine and Molecular Imaging under two Editors for more than a decade. He is a Distinguished Fellow of the American College of Nuclear Medicine and a Senior Member of the Mexican Academy of Surgery. Before joining Perspectum, Carlos managed the hepatology research at the Texas Digestive Disease Consultants (TDDC, the largest GI medical private practice in the USA). During his time at TDDC, Carlos positioned the hepatology research site as a top enroller for NASH clinical trials with the lowest screen failure rate among all US sites for multiple trials.